Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Almac Introduces QP Facilitation Programme for Conducting Trials in the European Union

Published: Thursday, June 14, 2012
Last Updated: Thursday, June 14, 2012
Bookmark and Share
Programme vastly simplifies and expedites the QP release process.

Almac has announced the Qualified Person (QP) Facilitation Programme; a value-add enhancement to Almac’s current suite of QP services.

Offered to global clients importing investigational medicinal products (IMP) into the European Union for clinical trial, this solution has been developed to alleviate the complex logistical challenges surrounding the QP Release process as well as provide a deeper level of consulting during this critical stage of clinical trial distribution.

This latest addition to the Almac portfolio is complementary to the already extensive range of services including packaging, labelling and global distribution of clinical supplies.

Directly, the on-site QP Facilitation Programme enhances Almac’s QP services portfolio which currently includes regulatory guidance, global auditing and import testing.

To simplify and expedite the often complicated QP Release process, an Almac Quality Compliance Manager will be placed at the client site in order to explain the release processes and to clearly define the responsibilities for both the sponsor and Almac.

Features of the program include access to a dedicated Quality Compliance Manager on-site that provides supply chain assessment, assembly and completion of relevant documentation necessary for QP Release, and an overall better understanding of all information pertaining to the QP release process.

In addition to reducing the burden of handling this process internally, clients will receive unique, study specific guidance from an experienced Quality Compliance Manager who is an expert in the QP Release process.

“The QP Facilitation Programme, through face-to-face interaction, will work to eliminate issues with the QP Release process and effectively remove the preparation for QP Release from the critical path,” said Paul O’Connor, Global Vice President Quality at Almac.

Paul continued, “We believe this service to be a tremendous benefit to clients with limited internal resources or those unfamiliar with the QP Release process.”

By participating in the QP Facilitation Programme, Almac clients will find the QP Release process more straightforward and accomplish necessary documentation in a more timely fashion.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Expands Asia Pacific Presence
Company opens new regional headquarters and clinical trial supply facility in Singapore.
Thursday, July 16, 2015
Novozymes Biopharma Announces Collaboration with Almac
Combined service offers drug development companies efficiencies in time and resource.
Tuesday, October 22, 2013
Almac Expands US & UK Commercial Facilities
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.
Tuesday, October 22, 2013
Almac Announces Further Expansion and 229 New Jobs
Dual expansion with completion of a new non-GMP drug development facility.
Monday, June 17, 2013
Almac Launches US Commercial Packaging Operations in Audubon
Company also announces launch of new client partnership.
Monday, May 20, 2013
Almac Receives FDA Inspection Approval
Successful inspection of analytical facilities at Almac’s Craigavon Headquarters, Northern Ireland from the US FDA.
Thursday, February 21, 2013
Almac Doubles Drug Product Development Capacity with a New Non-GMP Facility
New facility offers clients greater flexibility and speed in formulation and process development.
Tuesday, January 15, 2013
Charlie Morris Appointed to Almac’s Clinical Technologies Executive Team
Mr. Morris joins Almac as Vice President of new products and services.
Thursday, December 13, 2012
Almac Concludes Commercial API Manufacturing Facility Expansion Plans
Almac’s expansion is near completion and will be operational by the end of the year.
Tuesday, October 09, 2012
Almac Expands UK Commercial Capacity
Acquisition of new Noack N 623 blister packaging line from Romaco.
Friday, October 05, 2012
Almac Installs Uhlmann Blister Line in New US Commercial Packaging Facility
Acquisition of a high-speed blister line in Audubon, PA.
Monday, July 02, 2012
Almac Adds High-Speed Clinical Trial Blistering Equipment at US HQ
Almac acquires PharmaWorks TF3 machine to fulfil customer's needs by increasing blistering capacity.
Tuesday, May 15, 2012
Almac Strengthens Board with Appointment of New Financial Director
Kevin Stephens’ promotion to FD is set to further enhance the Group’s financial performance and programme for international growth.
Tuesday, April 10, 2012
New Building will Help Almac Serve Customers from Argentina to Zimbabwe
New £3m building opens at Craigavon, UK headquarters.
Tuesday, April 10, 2012
Almac Expands in US with Addition of Commercial Packaging Facility in Audubon, PA.
Expansion with $10m investment in a new 100,000ft2 commercial facility in Audubon.
Monday, March 12, 2012
Scientific News
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Common Drug Presents Fracture Risk To Older Women
Researchers are urging caution in prescribing one of the world’s most commonly issued drug groups, citing links to increased fracture risks in older Australian women.
Combining Epigenetic Therapies and Immunotherapies Improves Cancer Outcomes
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs.
LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos